HCPCS G0555 is officially defined as "Provision of replacement patient electronics system (e.g., system pillow, handheld reader) for home pulmonary artery pressure monitoring." HCPCS G0555 is referenced in 10 tracked payer policy changes from Humana, Capital Blue Cross, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0555 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
This is a new Medicaid policy for Virginia establishing coverage criteria for various cardiac devices including automated external defibrillators, ICDs, wireless PAP sensors, and cardiac monitoring. The policy defines specific eligibility requirements and explicitly excludes coverage for cardiac contractility modulation systems and carotid sinus devices.
Capital Blue Cross added preauthorization requirements for Keytruda Qlex (J9999) and Grafapex (J0614), and for new aflibercept, denosumab, IVIG and ustekinumab products under J3590, Q5157, J1599 and Q5137, with the changes effective March 1, 2026. Policy updates effective February 1, 2026 and March 1, 2026 also removed preauthorization for procedure code 48556 for commercial plans and for procedure codes 64596 and 64598 for commercial plans, and for procedure codes 64570 and L8681 for Medicare Advantage.
Premera's January 2025 update adds Carelon imaging, genetic testing and radiation oncology guideline changes for dates of service on and after April 20, 2025, and adds new Insulin Therapy and SGLT2 Inhibitors pharmacy policies effective January 1, 2025. It also adds Kisunla to the amyloid antibody policy and lists coding updates that now require review for medical necessity and prior authorization, including amyloid antibody code J0175, folate antimetabolite code J9292, and sickle cell disease code J3392.
Humana's Medicare Advantage policy on transcatheter and device-based hemodynamic procedures (policy HUM-1045-011) was revised with an effective date of 11/02/2026. The change summary lists this revision as an annual review with no coverage change, so the existing position carries forward: Humana states that implanted IVC and left atrial pressure monitors, and the subcutaneous heart failure decompensation monitor, are not medically reasonable and necessary. Carotid sinus baroreflex therapy has stated clinical criteria, and renal denervation and pulmonary artery pressure sensors follow CMS national coverage determinations 20.40 and 20.36.
Humana Medicare Advantage updated its policy on transcatheter and device-based hemodynamic management procedures effective 08/03/2026. The policy clarifies coverage criteria for implantable carotid sinus baroreflex activation therapy (BAT) for heart failure, requires enrollment in approved IDE studies or strict clinical criteria including LVEF ≤35% and specific biomarker thresholds, and references CMS National Coverage Determinations for pulmonary artery pressure sensors and renal denervation procedures. All services must meet medical necessity standards and contraindication exclusions.
Humana Medicare Advantage has established new coverage criteria for implantable carotid sinus baroreflex activation therapy for heart failure and confirmed coverage follows CMS guidelines for pulmonary artery pressure sensors and renal denervation procedures. The policy excludes coverage for left atrial pressure monitoring and inferior vena cava hemodynamic monitoring devices.
BCBS Rhode Island has updated multiple policies with various effective dates from October 1 to December 1, 2025. Key changes include removing prior authorization for genomic testing codes 81450 and 81451, covering cardiac monitoring codes for Medicare Advantage, and shifting several DME codes to use online authorization tools instead of traditional medical policies.
Aetna considers validated home blood pressure monitors medically necessary as an alternative to ambulatory blood pressure monitoring to confirm hypertension in members age 18 and older with office readings greater than 140 systolic or 90 diastolic. Validated blood pressure monitors are considered medically necessary for members receiving hemodialysis or peritoneal dialysis in the home, and validated blood pressure cuffs are considered medically necessary durable medical equipment for members with hypertension. Self-contained pacemaker monitors, including audible and visible signal monitors, digital electronic monitors, and a specialized telephone attachment for trans-telephonic transmission of results, are considered medically necessary for members with cardiac pacemakers. Automated oscillometer serial blood pressure monitors for home use, AngelMed Guardian, CardioMEMS pillow and components, home and implantable congestive heart failure monitors, implantable inferior vena cava sensors, implantable wireless pulmonary artery pressure monitors for heart failure, Zoll Heart Failure and Arrhythmia Management System, bioelectrical impedance analysis, and non-invasive central blood pressure assessment with SphygmoCor are considered experimental, investigational, or unproven. Pulse tachometers do not meet Aetna's definition of covered durable medical equipment.
Aetna considers validated home blood pressure monitors medically necessary as an alternative to ambulatory blood pressure monitoring to confirm hypertension in members age 18 and older with office readings greater than 140 systolic or 90 diastolic, when the cuff is prescribed by a physician, is an arm device, has the correct cuff size assessed and provided by the vendor, and only one cuff per 5 years is considered medically necessary. Validated blood pressure monitors are also considered medically necessary for members receiving hemodialysis or peritoneal dialysis in the home, and self-contained pacemaker monitors are considered medically necessary for members with cardiac pacemakers. Pulse tachometers do not meet Aetna's definition of covered DME, and the following are considered experimental, investigational, or unproven: AngelMed Guardian, automated oscillometer serial blood pressure monitors for home use, bioelectrical impedance analysis, CardioMEMS, home congestive heart failure telemonitoring devices, implantable congestive heart failure monitors, the implantable inferior vena cava sensor, non-invasive central blood pressure assessment with the SphygmoCor System, and the Zoll Heart Failure and Arrhythmia Management System for monitoring pulmonary fluid levels. The bulletin is titled CPB 0548, reviewed 2025-08-22, with a last review of 08/21/2026.
Already effective July 1, 2025, Louisiana Blue accepts only the CAQH application for professional credentialing and recredentialing, and the Louisiana Standardized Credentialing Application was accepted for participating providers until June 30. Added codes in the Diagnostic and Therapeutic Services and Outpatient Procedure Services code ranges have effective dates of January 1, 2025 and April 1, 2025, including 15013, 15014, 38226 and 38227. For infusion therapy, the prior authorization must include all codes billed, including administration codes, or penalties will be applied to the claim.
Watch G0555
Get one email when a payer policy names G0555, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for G0555
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for G0555 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.